What is sermorelin, and what is it studied for?
Sermorelin is the first 29 residues of human growth-hormone-releasing hormone, C-amidated, formula C149H246N44O42S, mass 3357.9, the shortest fragment with full activity at the GHRH receptor. It was formerly marketed as a pharmaceutical under the name Geref, since discontinued in the United States, and it is the reference GHRH analogue in secretagogue research and the backbone the CJC-1295 variants modify. The material here is for in-vitro research only.
What is the structure of Sermorelin?
Twenty-nine residues of native sequence with a C-terminal amide and no substitutions, including a methionine at position 27 that is the molecule's oxidation-prone site and an N-terminal tyrosine. Mass 3357.9 is confirmed by MALDI-MS on the current certificate; the April 2026 certificates use that method.
| Identifier | Value |
|---|---|
| Molecular formula | C149H246N44O42S |
| Molecular weight | 3357.9 g/mol |
| Residues | 29 |
| CAS number | 86168-78-7 |
| PubChem CID | 16132413 |
| Current lot | SERMO5-0318 |
How is Sermorelin thought to work?
Agonist at the GHRH receptor on pituitary somatotrophs, raising cAMP and releasing growth hormone in the models that measure it. Rivier, Spiess, Thorner and Vale characterised the parent factor in 1982, and the 1-29 fragment was identified as the minimum fully active sequence.
Which research areas use Sermorelin?
| Area | Typical models and endpoints |
|---|---|
| GHRH receptor pharmacology | cAMP and growth-hormone release assays in pituitary cell cultures. |
| Secretagogue reference | The standard comparator for CJC-1295 variants and tesamorelin in the same assays. |
| Peptide stability | Native-sequence susceptibility to dipeptidyl-peptidase cleavage and methionine oxidation. |
| Analytical chemistry | A 29-mer standard for MALDI versus LC-MS/MS identity comparisons. |
What does the published literature show?
Rivier et al. (Nature, 1982) characterised growth-hormone-releasing factor from a pancreatic tumour, the source of the 1-29 sequence. Sermorelin was an approved diagnostic and therapeutic product in the United States until its discontinuation; that history concerns a regulated pharmaceutical and is context only. Research use of the material here is in-vitro and preclinical.
How is Sermorelin handled in the laboratory?
Dissolves in water with gentle swirling. Methionine at position 27: protect from light and air, minimise headspace. Store lyophilized at minus 20 °C; aliquot and freeze; avoid repeated freeze-thaw. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.
What does the current certificate show?
Lot SERMO5-0318 tested at 99.8% purity by RP-HPLC (214 nm), identity confirmed by MALDI-MS, endotoxin ≤0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 5 mg per vial at $60, for laboratory research only.
Certificate history for Sermorelin
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| SERMO5-0318 | Apr 3, 2026 | 5 mg | MALDI-MS | 99.8% | 6.36 mg | Current |
Frequently asked questions
How does sermorelin differ from CJC-1295 without DAC?
Sermorelin is the native 1-29 sequence. Modified GRF(1-29) carries four substitutions that resist enzymatic cleavage. Same receptor, different stability, different masses.
What does the current certificate show?
Lot SERMO5-0318: identity by MALDI-MS at 3357.9, purity 99.8% by RP-HPLC at 214 nm, content 6.36 mg against a 5 mg label, endotoxin below 0.05 EU/mL. Issued 3 April 2026.
Why is the content 27% over the label?
Fills are set to meet or exceed the label and this April lot sits at the top of the catalogue's fill distribution. Use the certificate's 6.36 mg, not the label, in any calculation.
References
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278.
- PubChem CID 16132413, Sermorelin. National Library of Medicine. Read 2 October 2026.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
Sermorelin 5 mg
$60 per vial
Lot SERMO5-0318 · 99.8% RP-HPLC (214 nm) · certificate published
View productRelated
- CJC-1295 (no DAC) research guide · CJC-1295 (no DAC) 10 mg
- Ipamorelin research guide · Ipamorelin 5 mg
- Kisspeptin-10: the decapeptide from metastin, the KISS1R receptor, and what a 10 mg certificate shows
- How long does a reconstituted peptide last?
- The three residues that oxidise, and the +16 that gives it away
- What the issued date on a certificate of analysis tells you
- Glossary of certificate terms
